ライフサイエンスコーパス: Kawasaki disease

1 st that HCoV-NH infection is associated with Kawasaki disease.

2 rre syndrome, skin blistering syndromes, and Kawasaki disease.

3 tions from a 6-month-old infant with classic Kawasaki disease.

4 ith superantigen-mediated diseases including Kawasaki disease.

5 ammatory arthritis, rheumatoid arthritis and Kawasaki disease.

6 MRA accurately defines CAA in patients with Kawasaki disease.

7 aphy findings in patients with CAA caused by Kawasaki disease.

8 , and the short- and long-term management of Kawasaki disease.

9 30th anniversary of the first description of Kawasaki disease.

10 the mainstay of the acute phase treatment of Kawasaki disease.

11 nary artery disease attributed to antecedent Kawasaki disease.

12 es have examined the Th17/Treg expression in Kawasaki disease.

13 ts identified with presumed late sequelae of Kawasaki disease.

14 athy, long QT syndrome, commotio cordis, and Kawasaki disease.

15 met American Heart Association criteria for Kawasaki disease.

16 ificantly elevated during the acute phase of Kawasaki disease.

17 standard initial therapy in the treatment of Kawasaki disease.

18 as the top pathway regulated by microRNAs in Kawasaki disease.

19 ion in vasculitis by using a murine model of Kawasaki disease.

20 nderstanding of the late cardiac sequelae of Kawasaki disease.

21 itis syndromes, Henoch-Schonlein purpura and Kawasaki disease.

22 ification of the specific etiologic agent of Kawasaki disease.

23 e routine primary treatment of children with Kawasaki disease.

24 nts in the search for the etiologic agent of Kawasaki disease.

25 , in respiratory secretions of children with Kawasaki disease.

26 All children had acute Kawasaki disease 4 to 15 years before the PET study.

27 th the severity of symptoms in patients with Kawasaki disease, an acute inflammatory disease of child

28 iations between variants within the gene and Kawasaki disease and atrial fibrillation.

29 e of a 5-year-old boy who was diagnosed with Kawasaki disease and followed up by CT coronary angiogra

30 ecretions from 8 (72.7%) of 11 children with Kawasaki disease and from 1 (4.5%) of 22 control subject

31 work, were similar in both the patients with Kawasaki disease and healthy adult volunteers (82 +/- 14

32 common vasculitides of childhood, including Kawasaki disease and Henoch-Schonlein purpura.

33 still implicated in the aetiopathogenesis of Kawasaki disease and Henoch-Schonlein purpura.

34 nia and PET in 10 children with a history of Kawasaki disease and in 10 healthy young adult volunteer

35 aired in children with a previous history of Kawasaki disease and normal epicardial coronary arteries

36 Children with a history of Kawasaki disease and normal epicardial coronary arteries

37 Children with a previous history of Kawasaki disease and normal epicardial coronary arteries

38 terial wall of coronary aneurysms long after Kawasaki disease, and myofibroblasts likely play a centr

39 thnic variation of Henoch-Schonlein purpura, Kawasaki disease, and rarer vasculitides during childhoo

40 seases including toxic shock syndrome (TSS), Kawasaki disease, and sepsis.

41 e neurologic, cutaneous, articular syndrome, Kawasaki disease, and systemic lupus erythematosus to id

42 ildren younger than 6 years of age, treating Kawasaki disease, and treating polyarteritis nodosa, but

43 The vasculopathy of Kawasaki disease appears to be distinct from that of ath

44 challenges associated with the diagnosis of Kawasaki disease are also included.

45 onary aneurysms or regressed aneurysms after Kawasaki disease are at increased risk and require long-

46 Whether patients with Kawasaki disease are at risk of accelerated atherosclero

47 Diagnostic criteria for Kawasaki disease are problematic because many patients w

48 sions of predominant IgA antibodies in acute Kawasaki disease arterial tissue bind to an antigen pres

49 olymorphisms in Henoch-Schonlein purpura and Kawasaki Disease as well as the association between vari

50 iated bronchial epithelium indicate that the Kawasaki disease-associated antigen localizes to cytopla

51 samples were obtained from 186 children with Kawasaki disease at 24 h before IVIG therapy, followed b

52 d at high levels in blood samples from acute Kawasaki disease but not adenovirus-infected control pat

53 air of urinary proteins that are elevated in Kawasaki disease but not other febrile illnesses.

54 healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be

55 arteritis that histopathologically resembles Kawasaki disease, but the mechanism remains unclear.

56 The acute vasculitis of Kawasaki disease can result in coronary artery damage an

57 l tissue bind to an antigen present in acute Kawasaki disease ciliated bronchial epithelium and in a

58 ion of cytoplasmic inclusion bodies in acute Kawasaki disease ciliated bronchial epithelium has provi

59 microscopic studies of the antigen in acute Kawasaki disease ciliated bronchial epithelium indicate

60 g and its Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee organized a writing group to

61 mittee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease of t

62 valuate the algorithm performance using rare Kawasaki Disease datasets.

63 of infliximab to primary treatment in acute Kawasaki disease did not reduce treatment resistance.

64 epithelium has provided direction for future Kawasaki disease etiology studies.

65 Two recently proposed theories of Kawasaki disease etiology, the toxic shock syndrome toxi

66 dehyde-fixed medium-sized bronchi from acute Kawasaki disease fatalities and analysis of the protein

67 As children with Kawasaki disease grow up, adult cardiologists are likely

68 Patients with Kawasaki disease had higher levels of plasma IL-17A (25.

69 West Midlands than previously reported, and Kawasaki disease has a higher incidence than previously

70 In the United States, Kawasaki disease has now surpassed acute rheumatic fever

71 istent or remodeled coronary aneurysms after Kawasaki disease have a high rate of complications inclu

72 ternational and multidisciplinary efforts in Kawasaki Disease have resulted in recommendations for it

73 enesis, treatment, and long-term outcomes of Kawasaki disease, highlighting recent publications.

74 se in young adults that can be attributed to Kawasaki disease in childhood, we performed a retrospect

75 immune globulin is an effective therapy for Kawasaki disease in children, and recent data suggest th

76 ate the syndrome, although the occurrence of Kawasaki disease in epidemics and its resemblance to tox

77 Incidence of Kawasaki disease in Japan is 10 times higher than in the

78 Kawasaki disease in the very young infant is also discus

79 a cells infiltrate inflamed tissues in acute Kawasaki disease, including the coronary artery, and are

80 Resistance to intravenous immunoglobulin in Kawasaki disease increases the risk of coronary artery a

81 Conclusions and Relevance: Kawasaki disease is a hybrid condition at the junction o

82 Kawasaki disease is a systemic vasculitis of childhood;

83 Kawasaki disease is a vasculitis most commonly afflictin

84 Kawasaki disease is an acute inflammatory process of the

85 Kawasaki disease is an acute systemic vasculitis of chil

86 Kawasaki disease is an acute vasculitis of childhood tha

87 Kawasaki disease is an acute vasculitis of unknown etiol

88 Kawasaki disease is an acute, self-limited vasculitis of

89 Kawasaki disease is an acute, self-limited vasculitis of

90 Kawasaki disease is an acute, self-limited vasculitis of

91 Our findings provide further evidence that Kawasaki disease is an autoimmune-like disease.

92 The long-term treatment of children with Kawasaki disease is dependent on coronary artery status.

93 Kawasaki disease is most common in Japan.

94 Indeed, Kawasaki disease is no longer a rare cause of acute coro

95 Kawasaki disease is recognized as the most common cause

96 Kawasaki disease is the most common cause of acquired ca

97 Up to 25% of patients with untreated Kawasaki disease (KD) and 5% of those treated with intra

98 by angiography in children with a history of Kawasaki disease (KD) and pediatric heart transplant (TX

99 The clinical and epidemiological features of Kawasaki disease (KD) are consistent with an infectious

100 Human adenovirus (HAdV) infection mimics Kawasaki disease (KD) but can also be detected in KD pat

101 laboratory inflammatory markers early after Kawasaki disease (KD) diagnosis.

102 Kawasaki disease (KD) is a multisystem vasculitis that p

103 Kawasaki Disease (KD) is a potentially fatal acute vascu

104 Kawasaki Disease (KD) is a rare acute febrile illness du

105 Kawasaki disease (KD) is a self-limited, systemic vascul

106 Kawasaki disease (KD) is a vasculitis of young childhood

107 Kawasaki disease (KD) is an acute inflammatory illness m

108 Kawasaki disease (KD) is an acute pediatric vasculitis i

109 Kawasaki disease (KD) is an acute vasculitis of young ch

110 Kawasaki disease (KD) is an acute, inflammatory, and sel

111 Kawasaki disease (KD) is an acute, self-limited vasculit

112 Kawasaki disease (KD) is an enigmatic, self-limited vasc

113 Acute Kawasaki disease (KD) is difficult to distinguish from o

114 Kawasaki disease (KD) is the leading cause of pediatric

115 Kawasaki disease (KD) is the most common acquired cardia

116 Kawasaki disease (KD) is the most common acquired cardia

117 In developed nations, Kawasaki disease (KD) is the most common cause of acquir

118 Kawasaki disease (KD) is the most common cause of acquir

119 Kawasaki disease (KD) is the most common cause of acute

120 Importance: Kawasaki disease (KD) is the most recognized vasculitis

121 s of coronary arterial inflammation in acute Kawasaki disease (KD) is unclear.

122 to compare the indices of vascular health in Kawasaki disease (KD) patients to those of control subje

123 entified in ciliated bronchial epithelium of Kawasaki disease (KD) patients using a synthetic antibod

124 The etiology and pathogenesis of Kawasaki disease (KD) remain unknown.

125 ntravenous immunoglobulin (IVIG) response in Kawasaki disease (KD), a vasculitis preferentially affec

126 st persistent myocardial abnormalities after Kawasaki disease (KD), the long-term effects on cardiac

127 lobulin (IVIG) is the treatment of choice in Kawasaki disease (KD).

128 th intravenous immunoglobulin for incomplete Kawasaki disease (KD).

129 Patients with Kawasaki disease (kDa) may develop coronary arterial les

130 5%) of 22 control subjects (children without Kawasaki disease matched by age and the time the specime

131 (c.742+871A>G) allele-positive patients with Kawasaki disease (n = 208) and 1 patient with idiopathic

132 have been published, in Behcet's disease and Kawasaki disease; none of the genes identified in these

133 e confirmed, our findings suggest a model of Kawasaki disease pathogenesis whereby miR-145 modulates

134 scovery of microRNAs that may participate in Kawasaki disease pathogenesis.

135 A recent study in a Japanese population of Kawasaki disease patients at high risk for IVIG resistan

136 Consequently, only recently have Kawasaki disease patients reached adulthood and come to

137 taneous intervention have been used to treat Kawasaki disease patients who develop myocardial ischemi

138 use IVIG as a second-line therapy for those Kawasaki disease patients who have persistent or recrude

139 l extracellular vesicles isolated from acute Kawasaki disease plasma samples.

140 avenous immunoglobulin and aspirin) in acute Kawasaki disease reduces the rate of treatment resistanc

141 nisolone to conventional primary therapy for Kawasaki disease reduces the risk of coronary-artery abn

142 The cause of Kawasaki disease remains unknown and this presents many

143 The cause of Kawasaki disease remains unknown, but fortunately intrav

144 Therapy for Kawasaki disease resistant to intravenous immune globuli

145 In patients with Kawasaki disease, serial evaluation of the distribution

146 A history of antecedent Kawasaki disease should be sought in all young adults wh

147 The 5th International Kawasaki Disease Symposium was held in May 1995 in Fukuo

148 ere significantly lower in the patients with Kawasaki disease than in the control subjects (263 +/- 6

149 y resistance was higher in the patients with Kawasaki disease than in the healthy adult volunteers (3

150 flow reserve were lower in the patients with Kawasaki disease than in the healthy young adult volunte

151 Kawasaki disease, the most common cause of acquired hear

152 in a subset of macrophages in acute inflamed Kawasaki disease tissues.

153 cts (age 10 to 25 years) with known CAA from Kawasaki disease underwent coronary MRA using a free-bre

154 may be a potential therapeutic candidate for Kawasaki disease vasculitis and other IL-1 mediated infl

155 The estimated annual incidence of Kawasaki disease was 5.5 per 100000 in children younger

156 Kawasaki disease was associated with higher IL-17A and I

157 PURPOSE OF REVIEW: Kawasaki disease was first described in Japanese in 1967

158 le association between HCoV-NH infection and Kawasaki disease, we conducted a case-control study.

159 croRNAs play in modifying gene expression in Kawasaki disease, we studied microRNAs from whole blood

160 d of 12 patients with acute and convalescent Kawasaki disease were analyzed by sequencing of small RN

161 ng our DP TDT in a real dataset in analyzing Kawasaki disease with 187 families and 906 SNPs.

162 Treatment of acute Kawasaki disease with intravenous immune globulin and as

163 a family-based allelic association study for Kawasaki Disease, with data hosted in three different co